Our Mission

Mission Statement

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. Founded in 2014, MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) a 501(c)(3) nonprofit.

Public Benefit

What is the Benefit of a Public Benefit Corporation?

 

Shared Guiding Principles

Patients First. Learn About Our Purpose and Mission.

Who We Are

We Strive for Public Benefit. We Are the Members of MAPS PBC. 

What is a Public Benefit Corporation?

A Public Benefit Corporation is a new type of corporation that is driven by values that promote sustainability, accountability, and transparency.

  • Sustainability: We use profits to continue research to benefit society.
  • Accountability: We take our impact on society and the environment into consideration.
  • Transparency: We are required to report and share progress towards our impact on society.

Our Relationship to MAPS

MAPS Public Benefit Corporation (MAPS PBC), is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS).

The Mission of MAPS

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

Shared Guiding Principles

  • Patients first and profits for care – Accessible mental health treatments for those who are in need.
  • Transparency — Commitment to open-science principles.
  • Passion and Perseverance — We persist in the face of challenges.
  • Intelligent Risk — Our decisions are informed by research.
  • Trust and Accountability — We value integrity and honesty, and embrace high standards.

*MAPS Public Benefit Corporation is owned by one shareholder.

MAPS PBC is Committed to Collective Liberation

MAPS PBC is committed to collective liberation. We acknowledge the existence of historic and systemic oppression and recognizes that a truly liberated future can only exist if all people, including and especially those who have been impacted by these injustices, are included in its creation. Collective liberation recognizes that all of our struggles are intimately connected, and that within systems of oppression, everyone suffers.

Who We Are

MAPS Public Benefit Corporation

Established in 2014

Come work with us!

Board of Directors

Amy Emerson

Amy Emerson Chief Executive Officer (CEO)

Read Bio
Amy Emerson

Amy Emerson

Chief Executive Officer (CEO)

Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization. As the Chief Executive Officer, Amy has led the growth and development of this new subsidiary and is responsible for overall global regulatory strategy and implementation of research programs with a focus on the MDMA-assisted psychotherapy program within MAPS PBC.

Amy started as a pro bono consultant at MAPS in 2003, and since then has built MAPS’ clinical department while managing the MDMA Clinical Development Program with a focus on the PTSD indication. In 2014, MAPS Public Benefit Corporation was incorporated to focus on psychedelic drug development, therapist training programs, and future sales of prescription psychedelics prioritizing public benefit above profit.

Amy brings decades of pharmaceutical development and research experience in Phase 1 through Phase 3 Randomized Controlled Trials including supporting three successful regulatory approvals for new biologics. Her professional experience at Novartis, Chiron, and other pharmaceutical companies (1993-2009) spans various fields including immunology, oncology, and vaccines. Pursuing her love of science and nature cultivated while growing up in the woods of Alaska she earned her B.S. in genetics and cell biology from Washington State University in 1992 to prepare for a career in research. Amy is passionate about being a mother and the work of bringing the potential of psychedelics for healing further into the consciousness of the world, leaving a better world for the following generations. She has a lifelong love of travel, living abroad with her husband, exploring in nature, and cooking with her family.

 

 

 

Rick Doblin, Ph.D.

Rick Doblin, Ph.D.

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and empty rooms from three children who are all in college.

Dawn McCollough

Dawn McCollough

Board Chair

Dawn McCollough has overseen global clinical development involving thousands of patients across numerous indications for nearly 25 years.  In addition to her role at MAPS PBC, she owns a consulting company that assists pharmaceutical, biotech and CRO clients.

Previously, she headed clinical operations functions in start-up Biotech organizations, headed Medical Research Operations and Research Team in Late Stage Development at Biogen. Prior to that, Dawn was Head of the Global Monitoring Organization for North America at Novartis Vaccines and Diagnostics, based in Cambridge, MA. Dawn began her career with Novartis as Global Head of Clinical Trial Governance based in Siena, Italy. Throughout the course of her career, she has participated in the development of numerous drug products from concept to approval. Dawn has been chosen as a top Women’s Leader within previously affiliated organizations.

Dawn has an entrepreneurial spirit and is passionate about developing new options for patients and for people. Dawn enjoys ultra running and has a very strong connection with animals, and anything outdoors.

 

 

Matt Neal

Matt Neal

Matt Neal joined Atara Biotherapeutics in 2019 as the Head of Regulatory Affairs Operations. Prior to that, Matt was the Head of Product Management for the InSight Suite of Regulatory Information Management Solutions at Parexel, Inc., and partnered with Microsoft to deliver first-of-its-kind life science innovation with Office 365 to “Change The Way You Work.” Before joining Paraxel, Matt was a Director of Regulatory & Safety Operations at Amgen, Inc. (2003-2016) and was one of the pioneering members of the Regulatory Submissions Department for GlaxoSmithKline (1996-2003). Matt has been publishing and submitting electronic dossiers to the FDA since 1996, and submitted the very first fully electronic NDA for GSK in 1999.

Miriam Volat

Miriam Volat

Miriam Volat works personally and professionally to promote health in all systems. She works as a facilitator, researcher, educator, and community organizer to increase broad-based community and ecological resiliency, especially in native communities. Her work focuses on the intersection of biological and socio-cultural diversity. Miriam has never stopped exploring nutrient cycles and soil ecology, the emphasis of her M.S. work in the UC Davis Vegetable Crops Dept. She also has degrees in political science and environmental studies.

Her life’s work at Riverstyx now includes supporting psilocybin and MDMA research including those involving religious clergy, deep eco-ministry for direct-experience religious transformation, composting toilets and human bodies, and indigenous medicine, land, and cultural conservation, supporting balanced relationships between humans and our ecosystem. As a mom, she is fortunate her daughter, Cora, also supports her work and participates passionately on her many adventures. Riverstyx and Miriam are unequivocal in their commitment to the mission of MAPS and MAPSBC.

Senior Leadership Team

Amy Emerson

Amy Emerson Chief Executive Officer (CEO)

Read Bio
Amy Emerson

Amy Emerson

Chief Executive Officer (CEO)

Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization. As the Chief Executive Officer, Amy has led the growth and development of this new subsidiary and is responsible for overall global regulatory strategy and implementation of research programs with a focus on the MDMA-assisted psychotherapy program within MAPS PBC.

Amy started as a pro bono consultant at MAPS in 2003, and since then has built MAPS’ clinical department while managing the MDMA Clinical Development Program with a focus on the PTSD indication. In 2014, MAPS Public Benefit Corporation was incorporated to focus on psychedelic drug development, therapist training programs, and future sales of prescription psychedelics prioritizing public benefit above profit.

Amy brings decades of pharmaceutical development and research experience in Phase 1 through Phase 3 Randomized Controlled Trials including supporting three successful regulatory approvals for new biologics. Her professional experience at Novartis, Chiron, and other pharmaceutical companies (1993-2009) spans various fields including immunology, oncology, and vaccines. Pursuing her love of science and nature cultivated while growing up in the woods of Alaska she earned her B.S. in genetics and cell biology from Washington State University in 1992 to prepare for a career in research. Amy is passionate about being a mother and the work of bringing the potential of psychedelics for healing further into the consciousness of the world, leaving a better world for the following generations. She has a lifelong love of travel, living abroad with her husband, exploring in nature, and cooking with her family.

 

 

 

Berra Yazar-Klosinski, Ph.D.

Berra Yazar-Klosinski, Ph.D. Deputy Director and Head of Research Development and Regulatory Affairs

Read Bio
Berra Yazar-Klosinski, Ph.D.

Berra Yazar-Klosinski, Ph.D.

Deputy Director and Head of Research Development and Regulatory Affairs

Berra Yazar-Klosinski, Ph.D., is the Deputy Director and Head of Research Development and Regulatory Affairs of the 501(c)(3) non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). Dr. Yazar-Klosinski is responsible for development of strategic, catalytic, and capacity-building activities to facilitate research on the risk/benefit profile of psychedelics in compliance with the global regulatory landscape. She has been actively involved in the various stages of nonclinical and clinical development of MDMA-assisted psychotherapy, LSD-assisted psychotherapy, cannabis, and ibogaine.

After gaining experience in clinical research laboratories with Geron Corporation and Millennium Pharmaceuticals, Dr. Yazar-Klosinski joined MAPS in 2009 to work with an organization where profit wouldn't dictate the agenda of scientific research. Over the last 10 years, she has supported MAPS clinical research and regulatory affairs through all stages of growth. Dr. Yazar-Klosinski has developed a strong track record of success with FDA, state regulatory agencies and multiple regulatory agencies outside of the USA.

Dr. Yazar-Klosinski earned her B.S. in Biology with a minor in Drama from Stanford University and her Ph.D. in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz in 2010. She is a Turkish hunter-gatherer who is supporting the growth of her family and pets in harmony with the natural world as she works tirelessly to transform the future.

Corine de Boer, M.D., Ph.D.

Corine de Boer, M.D., Ph.D. Chief Medical Officer

Read Bio
Corine de Boer, M.D., Ph.D.

Corine de Boer, M.D., Ph.D.

Chief Medical Officer

Corine de Boer, M.D., Ph.D. is the Chief Medical Officer at MAPS Public Benefit Corporation.

She received her medical degree from Radboud University in Nijmegen, the Netherlands and completed residency and fellowship training in pediatrics and pediatric nephrology. Her Ph.D. was focused on peritoneal dialysis in children, and she joined the academic staff at the Radboud University after completing her training.

Before moving to the United States in 2000, she worked as a Pediatrician in the largest inner-city hospital (OLVG) in Amsterdam where she was responsible for in- and outpatient care in a multi-racial patient group including sickle-cell disease, thalassemia, and AIDS.

For the last 20 years, she has contributed to the development of meningococcal and hepatitis vaccines during her tenure at GSK vaccines (formerly Novartis Vaccines and Chiron Corporation) and Dynavax prior to starting her own consulting company where she provides strategic advice and support for a variety of clients working on biologics, small molecule/polymer therapeutics and vaccines.

She feels very fortunate to formally join the MAPS team after assisting them previously in the development of the Pediatric Plans for MDMA. The opportunity that psychedelics provide in the treatment of PTSD and other indications is an exciting scientific field where she feels honored to play a small part in.

Corine resides in beautiful Port Townsend, WA, with her husband and her Jack Russell Terrier where she can be found roaming the beaches, making (wearable) recycled art, and messing around in rowing shells and other boats.

Ana LaDou

Ana LaDou Chief Operating Officer (COO)

Read Bio
Ana LaDou

Ana LaDou

Chief Operating Officer (COO)

Ana LaDou serves as the Chief Operating Officer (COO) for MAPS Public Benefit Corporation (MAPS PBC). Ana is a dynamic leader and creative strategist who nurtures leaders, mobilizes teams, and develops strategic processes that result in stronger, scalable organizations. Ana specializes in leadership: providing it, supporting it, and developing it. She has worked on projects with local, national, and international reach where her ability to design straightforward strategies and gain consensus among the Board of Directors and outside stakeholders consistently results in innovative solutions and meaningful community impact. She graduated from Columbia University in New York, launched her career in marketing at Miramax Films, and maintains her ties to the industry. Her strengths in relationship building and collaborative leadership ensure ongoing support for the organization and meaningful change in their community. She is committed to her vipassana mindfulness and Nonviolent Communication (NVC) practices, and engaging Boards of Directors and executive leaders in deeper conversations and actions to address current cultural challenges.

Andrew “Mo” Septimus

Andrew “Mo” Septimus Chief Financial Officer (CFO)

Read Bio
Andrew “Mo” Septimus

Andrew “Mo” Septimus

Chief Financial Officer (CFO)

Andrew "Mo" Septimus is an experienced entrepreneur with a track record of managing multimillion-dollar raises and budgets, complex projects, and teams. He has worked in private equity and acted as CFO in various industries. Mo brings a compassionate, outgoing, and resourceful leadership style, coupled with practical optimism and a sense of humor. He enjoys craft beverages, hockey, herring, kiddish club, and long walks on the beach. Mo is from Queens, New York, and lives with his family in Surfside, Florida.

Michael Mithoefer, M.D.

Michael Mithoefer, M.D. Senior Medical Director for Medical Affairs, Training and Supervision

Read Bio
Michael Mithoefer, M.D.

Michael Mithoefer, M.D.

Senior Medical Director for Medical Affairs, Training and Supervision

Michael Mithoefer, M.D., is a psychiatrist living in Asheville, NC, with a research office in Charleston, SC. In 2000, he began collaborating with MAPS on the first U.S. Phase 2 clinical trial of MDMA-assisted psychotherapy. He and his wife Annie have since conducted two of the six MAPS-sponsored Phase 2 clinical trials testing MDMA-assisted psychotherapy for PTSD, as well a study providing MDMA-assisted sessions for therapists who have completed the MAPS-sponsored MDMA Therapy Training Program, and a pilot study treating couples with MDMA-assisted psychotherapy combined with Cognitive-Behavioral Conjoint Therapy. He is now Senior Medical Director for Medical Affairs, Training and Supervision at MAPS Public Benefit Corporation (MAPS PBC). He is a Grof-certified Holotropic Breathwork Facilitator, is trained in EMDR and Internal Family Systems Therapy, and has nearly 30 years of experience treating trauma patients. Before going into psychiatry in 1991, he practiced emergency medicine for ten years, served as medical director of the Charleston County and Georgetown County Emergency Departments, and has held clinical faculty positions at the Medical University of South Carolina. He has been board-certified in Psychiatry, Emergency Medicine, and Internal Medicine.

Jay Nair, Ph.D., P.M.P.

Jay Nair, Ph.D., P.M.P. Senior Director and Head of CMC

Read Bio
Jay Nair, Ph.D., P.M.P.

Jay Nair, Ph.D., P.M.P.

Senior Director and Head of CMC

Jay Nair, Ph.D., P.M.P., comes to us with over 30 years of expertise in chemistry, manufacturing, and controls (CMC) executive management in the pharmaceutical and biopharmaceutical industries. Over his career, he has worked at companies such as Bristol Myers Squibb (BMS), Baxter, Teva, and Cephalon. Since his position as Executive Director at BMS, he has been a management consultant in the areas of CMC, Regulatory and Project Management. He also consulted for private equity companies as a global due diligence expert, analyzing the FDA exposure and assessing the risk of target companies and their therapeutic assets. His clients included Pfizer, McKinsey & Co., Accenture, Capital Group of companies etc. Jay obtained his Ph.D. in Pharmaceutical Analysis from Boston University. He is a graduate of Indian Institute of Technology (IIT) Kanpur. Jay is also a certified Project Management Professional (PMP). Jay spends his downtime enjoying public speaking, philosophy, nature travel, yoga, and meditation.

Rebecca A. Matthews

Rebecca A. Matthews Director and Head of Clinical Operations

Read Bio
Rebecca A. Matthews

Rebecca A. Matthews

Director and Head of Clinical Operations

Rebecca A. Matthews is the Director and Head of Clinical Operations at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit. Rebecca is leading the Clinical Operations teams in conducting clinical trials around the globe in all indications and clinical programs supported by MAPS PBC and MAPS.

Rebecca began consulting with MAPS in 2009 and joined MAPS PBC full-time in 2015. Prior to her work at MAPS and MAPS PBC she worked in clinical research and development at Chiron/Novartis starting in 2001 with a focus in the indications of sepsis and vaccines.

Rebecca is drawn to the field of research and drug development to support the advancement of healthcare and to provide novel and improved treatments for the benefit of humankind. She is deeply passionate about this amazing journey and honored to be on the forefront of psychedelic medicine research. Rebecca earned her B.A. from UC Berkeley in 2000.

She resides in Northern California alongside her husband, two daughters and the family labradoodle and can be found starting impromptu dance parties, enjoying delicious tacos and playing in nature with family and friends.

Shannon C. Carlin, M.A., A.M.F.T.

Shannon C. Carlin, M.A., A.M.F.T. Director and Head of Training and Supervision

Read Bio
Shannon C. Carlin, M.A., A.M.F.T.

Shannon C. Carlin, M.A., A.M.F.T.

Director and Head of Training and Supervision

Shannon Carlin, M.A., AMFT, is the Director of Training and Supervision at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit. As the Director of Training and Supervision, Shannon oversees the development and implementation of the programs that provide training and supervision to prepare mental health and medical professionals to deliver MDMA-assisted psychotherapy in approved clinical settings. Shannon started working with MAPS in 2011 before joining MAPS PBC in 2016.

In her dedication to supporting people through growth and healing, Shannon has served as a co-therapist on MAPS-sponsored Phase 2 trials researching MDMA-assisted psychotherapy for anxiety associated with life-threatening illness and MDMA-assisted psychotherapy for severe PTSD. Shannon’s direct clinical work continues to inform the development and implementation of the training programs she oversees.

Shannon’s previous professional experience includes the development of community programs delivering resources, services, training, and support for healthy living, life skills, employment, and positive youth development. Her work has served adults with schizophrenia, bipolar, and substance use disorder, families and youth in a low-income residential setting, and high school students learning about moderation management of drug and alcohol use. In her lifelong commitment to address homelessness, Shannon volunteers with housing projects and shelters and completed a farm internship with the Homeless Garden Project.

Shannon received her master’s degree in Integral Counseling Psychology from the California Institute of Integral Studies and a bachelor’s degree in Cultural Anthropology from the University of California, Santa Cruz. An adventurer at heart, Shannon can be found in nature, backpacking, running, and dancing. She celebrates and cultivates relationship and community and is passionate about life, love, and thriving.

 

MAPS Public Benefit Corporation

Our Mission
Who We Are
Careers
News
FAQ
Contact Us

1115 Mission Street
Santa Cruz, CA 95060-9989

MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.